Perceptive Advisors OKUR Position
Exited3-Fund ConvergencePerceptive Advisors exited their position in OnKure Therapeutics, Inc. (OKUR) in Q2 2025, after holding the stock for 3 quarters.
The position was first reported in Q4 2024 and has been tracked across 3 quarterly 13F filings.
OKUR is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
About OnKure Therapeutics, Inc.
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
Full company profile →Short Interest
0.1%
0.1 days to cover
Perceptive Advisors OKUR Position History
Frequently Asked Questions
Does Perceptive Advisors own OKUR?
No. Perceptive Advisors exited their position in OnKure Therapeutics, Inc. (OKUR) in Q2 2025. They previously held the stock for 3 quarters.
How many hedge funds own OKUR?
3 specialist biotech hedge funds currently hold OKUR, including Cormorant Asset Management, Deep Track Capital, Tang Capital Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy OKUR?
Perceptive Advisors's position in OKUR was first reported in Q4 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's OKUR position increasing or decreasing?
Perceptive Advisors completely exited their OKUR position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
OKURCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →